January 2022
Inversago Pharma Completes Phase 1 Clinical Trial on First-in-Class, Peripheral CB1 Blocker and Provides Strategy Update
"Company has completed the Phase 1 Clinical Trial for its INV-202 molecule
Encouraging Phase 1 results and supportive preclinical package assist in the launch of Phase 2 clinical development
Metabolic disorders are a global epidemic1
MONTREAL--(BUSINESS WIRE)--Inversago Pharma Inc. (“Inversago”), the peripheral CB1 blockade company, announced today the successful completion of the Phase 1 Clinical Trial for its INV-202 molecule that focuses on treating metabolic disorder complications. Favorable safety, tolerability and pharmacokinetic results from the trial warrant further investigation, and the Company will actively pursue the advancement of INV-202 into later-stage clinical trials."